Literature DB >> 24128811

Andersen-Tawil syndrome, scarier for the doctor than for the patient? Who, when, and how to treat.

Arthur A M Wilde1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24128811     DOI： 10.1093/europace/eut326

Source DB:  PubMed          Journal:  Europace        ISSN： 1099-5129            Impact factor:   5.214


× No keyword cloud information.
  3 in total

1.  Flecainide ameliorates arrhythmogenicity through NCX flux in Andersen-Tawil syndrome-iPS cell-derived cardiomyocytes.

Authors:  Yusuke Kuroda; Shinsuke Yuasa; Yasuhide Watanabe; Shogo Ito; Toru Egashira; Tomohisa Seki; Tetsuhisa Hattori; Seiko Ohno; Masaki Kodaira; Tomoyuki Suzuki; Hisayuki Hashimoto; Shinichiro Okata; Atsushi Tanaka; Yoshiyasu Aizawa; Mitsushige Murata; Takeshi Aiba; Naomasa Makita; Tetsushi Furukawa; Wataru Shimizu; Itsuo Kodama; Satoshi Ogawa; Norito Kokubun; Hitoshi Horigome; Minoru Horie; Kaichiro Kamiya; Keiichi Fukuda
Journal:  Biochem Biophys Rep       Date:  2017-01-11

2.  Every face tells a story-unravelling a case of bidirectional ventricular tachycardia.

Authors:  Sakshi Sachdeva; Saurabh Kumar Gupta; Nitish Naik
Journal:  Indian Pacing Electrophysiol J       Date:  2020-06-29

3.  Propafenone is not effective for severe ventricular arrhythmias in Andersen-Tawil syndrome.

Authors:  Piotr Bienias; Anna Kostera-Pruszczyk; Maria Miszczak-Knecht; Michał Ciurzyński; Piotr Pruszczyk
Journal:  Arch Med Sci       Date:  2016-06-30       Impact factor: 3.318
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.